Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Measurement of the cellular deacetylase activity of SIRT1 on p53 via LanthaScreen® technology.

Robers MB, Loh C, Carlson CB, Yang H, Frey EA, Hermanson SB, Bi K.

Mol Biosyst. 2011 Jan;7(1):59-66. doi: 10.1039/c0mb00026d. Epub 2010 Oct 8.

PMID:
20931131
2.

Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approach.

Piper DR, Duff SR, Eliason HC, Frazee WJ, Frey EA, Fuerstenau-Sharp M, Jachec C, Marks BD, Pollok BA, Shekhani MS, Thompson DV, Whitney P, Vogel KW, Hess SD.

Assay Drug Dev Technol. 2008 Apr;6(2):213-23. doi: 10.1089/adt.2008.137.

PMID:
18471075
3.

The bacterial virulence factor NleA inhibits cellular protein secretion by disrupting mammalian COPII function.

Kim J, Thanabalasuriar A, Chaworth-Musters T, Fromme JC, Frey EA, Lario PI, Metalnikov P, Rizg K, Thomas NA, Lee SF, Hartland EL, Hardwidge PR, Pawson T, Strynadka NC, Finlay BB, Schekman R, Gruenheid S.

Cell Host Microbe. 2007 Sep 13;2(3):160-71.

4.
5.

Structural characterization of the molecular platform for type III secretion system assembly.

Yip CK, Kimbrough TG, Felise HB, Vuckovic M, Thomas NA, Pfuetzner RA, Frey EA, Finlay BB, Miller SI, Strynadka NC.

Nature. 2005 Jun 2;435(7042):702-7.

PMID:
15931226
6.

Regulation of type III secretion hierarchy of translocators and effectors in attaching and effacing bacterial pathogens.

Deng W, Li Y, Hardwidge PR, Frey EA, Pfuetzner RA, Lee S, Gruenheid S, Strynakda NC, Puente JL, Finlay BB.

Infect Immun. 2005 Apr;73(4):2135-46.

7.

Structure and biochemical analysis of a secretin pilot protein.

Lario PI, Pfuetzner RA, Frey EA, Creagh L, Haynes C, Maurelli AT, Strynadka NC.

EMBO J. 2005 Mar 23;24(6):1111-21. Epub 2005 Mar 10.

8.

Identification and characterization of NleA, a non-LEE-encoded type III translocated virulence factor of enterohaemorrhagic Escherichia coli O157:H7.

Gruenheid S, Sekirov I, Thomas NA, Deng W, O'Donnell P, Goode D, Li Y, Frey EA, Brown NF, Metalnikov P, Pawson T, Ashman K, Finlay BB.

Mol Microbiol. 2004 Mar;51(5):1233-49.

9.

Structural and biochemical characterization of the type III secretion chaperones CesT and SigE.

Luo Y, Bertero MG, Frey EA, Pfuetzner RA, Wenk MR, Creagh L, Marcus SL, Lim D, Sicheri F, Kay C, Haynes C, Finlay BB, Strynadka NC.

Nat Struct Biol. 2001 Dec;8(12):1031-6.

PMID:
11685226
10.

Crystal structure of LexA: a conformational switch for regulation of self-cleavage.

Luo Y, Pfuetzner RA, Mosimann S, Paetzel M, Frey EA, Cherney M, Kim B, Little JW, Strynadka NC.

Cell. 2001 Sep 7;106(5):585-94.

11.

Crystal structure of enteropathogenic Escherichia coli intimin-receptor complex.

Luo Y, Frey EA, Pfuetzner RA, Creagh AL, Knoechel DG, Haynes CA, Finlay BB, Strynadka NC.

Nature. 2000 Jun 29;405(6790):1073-7.

PMID:
10890451
12.

Enteropathogenic E. coli translocated intimin receptor, Tir, interacts directly with alpha-actinin.

Goosney DL, DeVinney R, Pfuetzner RA, Frey EA, Strynadka NC, Finlay BB.

Curr Biol. 2000 Jun 15;10(12):735-8.

13.
14.

Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells.

Kenny B, DeVinney R, Stein M, Reinscheid DJ, Frey EA, Finlay BB.

Cell. 1997 Nov 14;91(4):511-20.

16.

Soluble CD14 participates in the response of cells to lipopolysaccharide.

Frey EA, Miller DS, Jahr TG, Sundan A, Bazil V, Espevik T, Finlay BB, Wright SD.

J Exp Med. 1992 Dec 1;176(6):1665-71.

17.

Haemophilus influenzae lipopolysaccharide disrupts confluent monolayers of bovine brain endothelial cells via a serum-dependent cytotoxic pathway.

Patrick D, Betts J, Frey EA, Prameya R, Dorovini-Zis K, Finlay BB.

J Infect Dis. 1992 May;165(5):865-72.

PMID:
1373754
18.
19.

Characterization of the leukotriene D4 receptor in hyperreactive rat lung.

Metters KM, Frey EA, Ford-Hutchinson AW.

Eur J Pharmacol. 1991 Feb 26;194(1):51-61.

PMID:
1647964
20.

Reconstitution of the solubilized mu-opioid receptor coupled to a GTP-binding protein.

Frey EA, Gosse ME, Cote TE.

Eur J Pharmacol. 1989 Oct 17;172(4-5):347-56.

PMID:
2555207
21.
23.

The mu-opioid receptor in the 7315c tumor cell.

Tocque B, Jacobson AE, Rice KC, Frey EA.

Eur J Pharmacol. 1987 Nov 3;143(1):127-30.

PMID:
2826184
25.
27.
29.

Bromocriptine-induced changes in the biochemistry, physiology, and histology of the intermediate lobe of the rat pituitary gland.

Beaulieu M, Goldman ME, Miyazaki K, Frey EA, Eskay RL, Kebabian JW, Cote TE.

Endocrinology. 1984 May;114(5):1871-84.

PMID:
6325134
30.
31.

YM-09151-2: a potent antagonist for a peripheral D2-dopamine receptor.

Grewe CW, Frey EA, Cote TE, Kebabian JW.

Eur J Pharmacol. 1982 Jun 16;81(1):149-52. No abstract available.

PMID:
6126368
32.
33.

Biochemical and physiological studies of the beta-adrenoceptor and the D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland: a review.

Cote TE, Eskay RL, Frey EA, Grewe CW, Munemura M, Stoof JC, Tsuruta K, Kebabian JW.

Neuroendocrinology. 1982;35(3):217-24.

PMID:
6290925
34.

Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor.

Tsuruta K, Frey EA, Grewe CW, Cote TE, Eskay RL, Kebabian JW.

Nature. 1981 Jul 30;292(5822):463-5. No abstract available.

PMID:
7254340
35.

Supplemental Content

Support Center